Brian Skorney
Stock Analyst at Baird
(3.54)
# 944
Out of 5,182 analysts
121
Total ratings
45.35%
Success rate
7.7%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $95 → $112 | $92.48 | +21.11% | 7 | Apr 28, 2026 | |
| ANRO Alto Neuroscience | Maintains: Outperform | $41 → $38 | $24.27 | +56.57% | 6 | Apr 2, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $63 → $97 | $54.26 | +78.77% | 2 | Mar 9, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $20.98 | -28.50% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $38.62 | +60.54% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $9.59 | +442.23% | 4 | Aug 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $180 → $186 | $128.04 | +45.27% | 5 | Jul 31, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $52.75 | +129.38% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $18.04 | +77.38% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $180.67 | +41.14% | 17 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $652 → $587 | $744.44 | -21.15% | 15 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $100 | $127.75 | -21.72% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $12.61 | +137.91% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $13.28 | +50.60% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $24.75 | +1.01% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $340.18 | -36.80% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $5.63 | +397.78% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $8.62 | +352.44% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $426.01 | -23.71% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $28.62 | -65.06% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $0.57 | +47,160.63% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.76 | +59.57% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $0.58 | +51,481.84% | 3 | May 7, 2018 |
Mirum Pharmaceuticals
Apr 28, 2026
Maintains: Outperform
Price Target: $95 → $112
Current: $92.48
Upside: +21.11%
Alto Neuroscience
Apr 2, 2026
Maintains: Outperform
Price Target: $41 → $38
Current: $24.27
Upside: +56.57%
Xenon Pharmaceuticals
Mar 9, 2026
Maintains: Outperform
Price Target: $63 → $97
Current: $54.26
Upside: +78.77%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $20.98
Upside: -28.50%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $38.62
Upside: +60.54%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $9.59
Upside: +442.23%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $180 → $186
Current: $128.04
Upside: +45.27%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $52.75
Upside: +129.38%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $18.04
Upside: +77.38%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $180.67
Upside: +41.14%
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $744.44
Upside: -21.15%
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $127.75
Upside: -21.72%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $12.61
Upside: +137.91%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $13.28
Upside: +50.60%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $24.75
Upside: +1.01%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $340.18
Upside: -36.80%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $5.63
Upside: +397.78%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $8.62
Upside: +352.44%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $426.01
Upside: -23.71%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $28.62
Upside: -65.06%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $0.57
Upside: +47,160.63%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.76
Upside: +59.57%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $0.58
Upside: +51,481.84%